Skip to content Skip to footer
Jazz Pharmaceuticals' (NASDAQ: JAZZ) $935 million acquisition of Chimerix (NASDAQ: CMRX) marks a significant milestone in precision neuro-oncology, highlighting the growing potential of targeted therapies for brain cancers and signaling a shift towards biomarker-driven approaches in treating central nervous system tumors. The…